NCT07608705招募中1 期
An Open-label, Single-arm, Fixed-sequence Phase I Clinical Trial to Evaluate the Effect of HRS-1301 Tablets on the Pharmacokinetics of Midazolam and Atorvastatin Calcium Tablets in Healthy Participants
Shandong Suncadia Medicine Co., Ltd.1 个研究点 分布在 1 个国家目标入组 16 人开始时间: 2026年6月8日最近更新:
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 16
- 试验地点
- 1
研究概览
简要总结
This phase I study in healthy participants aims to assess the pharmacokinetics of midazolam and atorvastatin when administered alone and in combination with HRS-1301, and to assess the safety of HRS-1301 when administered alone and in combination with midazolam or atorvastatin.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Subjects must be aged ≥ 18 years and ≤ 55 years on the day of signing the informed consent form (ICF);
- •At screening, body mass index (BMI) must be ≥ 19.0 kg/m² and < 28 kg/m², with body weight ≥ 50.0 kg for males and ≥ 45.0 kg for females;
- •Physical examination, vital signs, electrocardiogram (ECG), posteroanterior and lateral chest X-ray/CT, abdominal ultrasound, and laboratory tests (including complete blood count, blood biochemistry, urinalysis, coagulation function, and thyroid function) were normal or abnormal but of no clinical significance;
- •Female participants must not be pregnant or lactating and must have negative pregnancy test results prior to investigational drug administration; participants must have had no unprotected sexual intercourse within two weeks prior to screening; female participants of childbearing potential and male participants with partners of childbearing potential must agree to comply with the contraception requirements for the duration specified in the protocol and have no plans to donate sperm or eggs;
- •Subjects who understand the study procedures and methods, voluntarily agree to participate in this trial, and provide written informed consent (ICF).
排除标准
- •Subjects with previous medical history or current diagnosis of cardiovascular, respiratory, digestive, urinary, hematological, endocrine, infectious, immunological, malignant neoplastic, neurological, or psychiatric/metabolic disorders/dysfunctions, or any other disease;
- •Subjects who have gastrointestinal, hepatic, renal, or other known diseases that may affect drug absorption, distribution, metabolism, or excretion, or that may reduce compliance;
- •Subjects who have experienced severe trauma or undergone major surgery within 3 months prior to screening, or who plan to undergo surgery during the trial period;
- •Subjects with a history of specific allergies, or with an allergic constitution, or with known hypersensitivity to any component of the investigational drug;
- •Subjects who have used any medication within 2 weeks prior to screening, or who are still within 5 half-lives of any medication at the time of screening;
- •Subjects who have participated in any other clinical trial of a drug or medical device within 3 months prior to screening, or who are still within 5 half-lives of a prior investigational drug at the time of screening;
- •Subjects who have donated blood ≥ 200 mL or experienced significant blood loss (≥ 400 mL) within 4 weeks prior to screening, or who have received a blood transfusion within 8 weeks prior to screening;
- •Subjects who have received a live (attenuated) vaccine within 4 weeks prior to screening or plan to receive such a vaccine during the trial period.
研究组 & 干预措施
HRS-1301 and Midazolam or Atorvastatin Group
Experimental
HRS-1301 tablets and Midazolam oral solution or Atorvastatin Calcium tablets, specified dose on specified days.
干预措施: HRS-1301 Tablets (Drug)
HRS-1301 and Midazolam or Atorvastatin Group
Experimental
HRS-1301 tablets and Midazolam oral solution or Atorvastatin Calcium tablets, specified dose on specified days.
干预措施: Midazolam oral solution (Drug)
HRS-1301 and Midazolam or Atorvastatin Group
Experimental
HRS-1301 tablets and Midazolam oral solution or Atorvastatin Calcium tablets, specified dose on specified days.
干预措施: Atorvastatin Calcium Tablets (Drug)
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
3 期
Comparing Oral and Nasal Midazolam for Sedation in Children as a premedicationCTRI/2026/01/100159Vinayaka Missions Kirupanandha Variyar Medical College and Hospitals60
尚未招募
不适用
A randomized, open-label, two-treatment, four-cohort, two-period, two-sequence, crossover, single-dose, oral comparative pharmacokinetic and bioequivalence study under fasting conditions.CTRI/2025/11/097344Birla Institute of Technology48
尚未招募
2/3 期
Comparative study between two routes of Midazolam administeration for sedation in children.CTRI/2024/07/071230Dr Reem Khatib100
尚未招募
不适用
Timing Of Midazolam İn Children Undergoing Adenotonsillectomy: Effects On Stress, Cortisol, And RecoveryNCT07622641Erzurum City Hospital100
招募中
2 期
Understanding of the effect of midazolam with nitrous oxide-oxygen compared to dexmedetomidine with nitrous oxide-oxygen in pediatric dentistry-a clinical trialCTRI/2026/03/105252pooja nellore46